SOHO 2023 | Efficacy and safety of mosunetuzumab monotherapy for R/R follicular lymphoma
Loretta Nastoupil
• 8 Sep 2023
Loretta Nastoupil, MD, The University of Texas MD Anderson Cancer Center, Houston, TX, shares safety and efficacy results from a Phase II trial investigating mosunetuzumab in patients with relapsed/refractory follicular lymphoma (R/R FL; NCT02500407). This fixed-duration monotherapy can be given in the outpatient setting, increasing patient access to effective immunotherapy. This interview took place at the Eleventh Annual Meeting of the Society of Hematologic Oncology (SOHO 2023) held in Houston, TX.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
